Add Yahoo as a preferred source to see more of our stories on Google. By Lisa Rapaport (Reuters Health) - A screening test for colon cancer that looks for "invisible" blood in stool may also predict a ...

September 20, 2010 — Stool DNA testing is currently too expensive to be reimbursed by Medicare for colorectal cancer screening, according to a new modeling study funded by the federal government.

Background: Current guidelines for screening of colorectal cancer do not offer specific recommendations for cessation of antithrombotic agents prior to fecal occult blood test (FOBT). Aim: To asess ...

When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often ...

Patients with a positive fecal occult blood test (FOBT) who did not undergo follow-up colonoscopy had a fourfold increased incidence of colorectal cancer, a Swedish population-based cohort study ...

Objective: To assess patient preferences for 1 of the recommended colorectal cancer screening options or stool DNA testing (sDNA), a novel noninvasive screening test. Study Design: Cross-sectional ...

Colorectal cancer (CRC) is the most common gastrointestinal cancer. In recent years CRC frequency and mortality have decreased slightly. 1 It is not clear whether this is because of changes in ...

(Reuters Health) - A screening test for colon cancer that looks for "invisible" blood in stool may also predict a heightened risk of premature death from other causes, a recent study suggests.